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opoulos et al. [4] can partly be explainedby thepatient populations
included in each study and the TJ proteins analysed. Their study
included patients with liver cirrhosis from various aetiologies,
including viral infection, which were deliberately excluded from
our study. It hasbeenshownthat theexpressionof claudinproteins
changes during development, differentiation, and in disease, in
response to stressors – including cytokines – in intestinal
epithelial cells [5,6]. Thus speciﬁc aetiological factors might
inﬂuence TJ expression.
Secondly, we assessed the role of intestinal macrophages in
cirrhosis. Intestinal macrophages have been shown to be
activated in Crohn’s disease [7] and in HIV enteropathy (manu-
script submitted) and have been shown to produce inﬂammatory
cytokines. Barrier defects are caused by disruption of normal
regulatory mechanisms that control gene expression, tight junc-
tion structure and cytoskeletal signalling [8]. We could show
for the ﬁrst time that intestinal macrophages are activated in
decompensated cirrhosis that may inﬂuence enterocyte TJ regula-
tion. Speciﬁcally, we could demonstrate an increase in IL-6 and
NO production, which have been previously shown to inﬂuence
intestinal permeability in inﬂammatory conditions, such as IBD
and necrotizing enterocolitis [6–8]. Although we have identiﬁed
important mechanisms associated with macrophage activation
in cirrhosis, it remains unclear to what extent these factors are
responsible for translocation of viable bacteria. Such studies
should be conducted using epithelial cultures exposed to
intestinal macrophages obtained from patients with liver disease.
These studies are currently ongoing in our laboratory.
The data and comments presented by Assimakopoulos et al.
highlight our ﬁndings that intestinal barrier TJ proteins play an
important role in bacterial translocation in liver cirrhosis.
Although we have identiﬁed activated intestinal macrophages
as potential players in the pathogenesis of BT in cirrhosis, we
have only reached the tip of the iceberg. Additional human ani-
mal and culture studies as well as more sophisticated methods
of measuring BT will shed light on how the intestinal epithelial
barrier, gut microbiota, and immune system interact and inﬂu-
ence disease progression in cirrhosis.
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JOURNAL OF HEPATOLOGYIntestinal GATA4 deﬁciency induces proximal ﬁbroblast growth
factor 15 expression and represses hepatic gluconeogenesisTo the Editor:
We have recently reported that conditional deletion of intestinal
GATA4 leads to an increased protection from obesity-associated
hepatic steatosis [1]. Using two independent murine models of
diet-induced hepatic steatosis, we demonstrated that intestine
speciﬁc GATA4 knockout (GATA4iKO) mice are protected from
high fat diet-induced hepatic steatosis. Our ﬁndings showed that
intestinal GATA4 deﬁciency was protective only in case where
hepatic de novo lipogenesis was involved, secondary to insulin
resistance. GATA4iKO mice were not protected upon induction
of steatosis via dietary deﬁciency of methionine and choline.
Methionine and choline-deﬁcient diet leads to hepatic steatosis
by suppressing VLDL release and beta-oxidation and does not sig-
niﬁcantly impact de novo lipogenesis. The underlying mechanism
for the observed beneﬁt is the ectopic upregulation of GLP-1 and
higher number of GLP-1 producing L-cells in the proximal intes-
tine of GATA4iKO mice.
Previous studies have shown that the levels of the important
enterokine ﬁbroblast growth factor 15 (FGF-15) are also upregu-
lated several fold in the proximal intestine of GATA4iKO mice
[2,3]. Under physiological conditions, transcript levels of intesti-
nal FGF-15 are restricted to the mucosa of the ileum and are sen-
sitive to bile acid availability and consequent activation of
farnesoid X receptor (FXR). However, it is not clear whether the
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Table 1. mRNA fold change and p value for genes involved in entero-hepatic bile acid and gluconeogenic gene regulation in fasted and 1 h post re-feeding of a
liquid diet (Ensure Plus™, Abbott GmbH, Austria) or 25 mmol cholic acid per kg body weight (Sigma, GmbH, Austria).
n.a., not available.
Data represent fold change and p value or mean ± SEM (n = 6 per group for plasma glucose; n = 3 per group for gene expression analysis).
⁄⁄p <0.01.
Gene name Fasted Re-fed
Fold p value Fold p value
Duodenum
Apical sodium dependent bile acid transporter 200.2 0.001 250.5 0.001
Fibroblast growth factor-15 (liquid diet) 42.3 0.001 72.7 0.001
Fibroblast growth factor-15 (cholic acid) n.a. n.a. 88.8 0.001
Jejunum
Apical sodium dependent bile acid transporter 641.9 0.001 327.9 0.001
Fibroblast growth factor-15 31.0 0.001 36.8 0.001
Ileum
Apical sodium dependent bile acid transporter 0.8 0.233 0.9 0.645
Fibroblast growth factor-15 0.3 0.001 0.2 0.001 
Liver
Cholesterol 7 alpha-hydroxylase 0.4 0.001 0.8 0.258 
Phosphoenolpyruvate carboxykinase 0.3 0.001 0.9 0.233
Glucose 6-phosphatase 0.7 0.010 1.0 0.696
Plasma glucose fasted Control GATA4iKO
Glucose (mg/dl) 73.33 ± 3.72 55.67 ± 1.90**
Letters to the Editorectopic FGF-15 produced in the proximal small intestine of
GATA4iKO mice is subjective to bile acid-mediated regulation.
FGF-15 is a crucial determinant of hepatic bile acid synthesis
and recent reports indicate an important role of this enterokine
in the regulation of postprandial hepatic gluconeogenesis, sec-
ondary to insulin [4]. Unlike insulin, which peaks at 15 min
post-feeding, ileal FGF-15 transcripts peak 1 h postprandially,
when bile acid concentrations increase in the small intestine
[4]. Hepatic effects of ectopic FGF-15 expressed from the proxi-
mal intestine and its regulation have not been studied.
Battle et al. have shown that transcript levels of hepatic cho-
lesterol 7-alpha hydroxylase (Cyp7a1) in GATA4iKO mice are
repressed [2]. This ﬁnding indicates that proximally produced
FGF-15 in GATA4iKO mice is physiologically active and can
repress hepatic bile acid synthesis. We have previously shown
that GATA4iKO mice are resistant to diet-induced obesity and
insulin resistance and maintain lower plasma glucose levels [5].
However, important questions as to whether its expression is
regulated by bile acids and whether it can in turn regulate hepa-
tic gluconeogenic gene expression have not been addressed. To
answer these questions, we performed quantitative real-time
PCR analysis of intestinal and hepatic transcripts in fasted and
1 h post-gavage control and GATA4iKO mice. We observed that
the expression of proximal FGF-15 in GATA4iKO mice is constitu-
tively upregulated even in the fasted state where bile acid avail-
ability is negligible (Table 1). However, in line with the
observations of Beuling et al. [3] we also found ileal FGF-15
transcripts in GATA4iKO mice to be severely repressed in both
fasted condition as well as 1 h post-gavage states. Additionally,
transcript levels of proximal FGF-15 after 1 h post-gavage of
cholic acid (25 mmol/kg in sodium bicarbonate buffer) were
induced 88 fold in GATA4iKO vs. control mice (Table 1). In
addition, we noticed that the mRNA expression of important glu-
coneogenic genes in the liver of fasted GATA4iKO mice was
downregulated (Table 1). As reported previously [2], we also
found repression of hepatic Cyp7a1 in fasted livers of GATA4iKO
mice (Table 1). GATA4iKO mice had lower body weight in fasted
(33.4 ± 1.3 vs. 27.1 ± 1.4) condition and reduced fasting glucose
levels compared with controls (Table 1).
These ﬁndings clearly indicate that the ectopic FGF-15
expression in the proximal intestine of GATA4iKO mice remains
physiologically active and impacts hepatic glucose metabolism.
Unlike ileal FGF-15, ectopic proximal expression of FGF-15 in
GATA4iKO mice persists even in fasted conditions. Our ﬁnding
of suppressed hepatic gluconeogenic gene expression could
explain the previous observation of reduced fasting plasma glu-
cose levels in high fat diet-fed GATA4iKO mice [5]. Further
studies aimed at understanding bile acid mediated effects in
proximal intestinal enterocytes in GATA4iKO mice are war-
ranted to identify possible interaction between intestinal FXR
and GATA4.
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